Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.



Daniel Plotkin

Project Manager

Daniel joined the Nuffield Department of Clinical Neurosciences as Project Manager of the national ALS/MND C9orf72 Cohort study ('ACORN') in October 2022, tasked with establishing a national register of motor neuron disease patients and family members carrying the C9orf72 gene mutation. This register will be pivotal in supporting the development of therapeutic strategies and neurochemical biomarkers for ALS. Daniel also manages the Oxford GENFI 3 study, focused on genetic factors leading to Frontotemporal dementia (FTD).  

Prior to joining the department, Daniel worked as Clinical Data Manager in Primary Care Health Sciences at the University of Oxford, with responsibility for all aspects of the data management of multiple clinical trials, overseeing the design, implementation and ongoing maintenance of the respective trial data platforms, ensuring successful submission of trial data for statistical and clinical analysis.   

Before joining Primary Care Health Sciences, Daniel worked as Clinical Data Manager in the Department of Tropical Medicine & Global Health at the University of Oxford, leading the operational administration and management of the ISARIC - WHO COVID-19 clinical data platform, eventually gathering acute clinical COVID-19 data from 62 countries around the world. 

Before the University of Oxford, Daniel worked as Clinical Data Manager in the Cancer Clinical Trials Unit at UCLH (University College London Hospitals), overseeing the submission and quality of clinical data for two later phase ovarian cancer trials.   


Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.

Docherty AB, Harrison EM et al  British Medical Journal (BMJ) 2020 May 22


What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol.

Sigfrid L et al   British Medical Journal (BMJ) Open. 2021 Mar 10;11(3):e043887. PMID: 33692181


Global outbreak research: harmony not hegemony.

ISARIC clinical characterisation group. The Lancet Infect Dis. 2020 Jul;20(7):770-772. Epub 2020 Jun 2.

PMID: 32502433


Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study

Thomas M Drake et al. The Lancet (2021)